Time-dependent risk of fracture in adults with type 2 diabetes receiving anti-diabetic drug: A one-stage network meta-analysis
CONCLUSIONS: Long-term use of thiazolidinediones elevates the risk of fracture among females with type 2 diabetes. There is no evidence eliciting fracture risk associated with other anti-diabetic drugs.PMID:38367257 | DOI:10.1002/dmrr.3780 (Source: Cell Research)
Source: Cell Research - February 17, 2024 Category: Cytology Authors: Yanjiao Shen Qingyang Shi Xinyu Zou Wentong Meng Haoming Tian Liang Du Sheyu Li Source Type: research
SGLT2 inhibitors improve cardiac function by improving intracellular calcium availability and optimizing the cell shape of cardiac myocytes
J Physiol. 2024 Feb 17. doi: 10.1113/JP286219. Online ahead of print.NO ABSTRACTPMID:38367225 | DOI:10.1113/JP286219 (Source: The Journal of Physiology)
Source: The Journal of Physiology - February 17, 2024 Category: Physiology Authors: Sven Kurbel Katarina Dodig- Ćurković Source Type: research
SGLT2 inhibitors improve cardiac function by improving intracellular calcium availability and optimizing the cell shape of cardiac myocytes
J Physiol. 2024 Feb 17. doi: 10.1113/JP286219. Online ahead of print.NO ABSTRACTPMID:38367225 | DOI:10.1113/JP286219 (Source: The Journal of Physiology)
Source: The Journal of Physiology - February 17, 2024 Category: Physiology Authors: Sven Kurbel Katarina Dodig- Ćurković Source Type: research
Investigation of MHR-nephropathy relationship and the effect of SGLT2is on MHR in patients with type 2 diabetes
ConclusionIn this study, results supporting the relationship between DN and MHR and the effect of SGLT2i drugs on MHR were found. The use of MHR value as a marker in clinical course monitoring and shaping the treatment according to these markers may be useful in terms of prediction and treatment of complications. (Source: Irish Journal of Medical Science)
Source: Irish Journal of Medical Science - February 17, 2024 Category: General Medicine Source Type: research
Mechanistic Modeling of Empagliflozin: Predicting Pharmacokinetics, Urinary Glucose Excretion, and Investigating Compensatory Role of SGLT1 in Renal Glucose Reabsorption
J Clin Pharmacol. 2024 Feb 16. doi: 10.1002/jcph.2413. Online ahead of print.ABSTRACTThe aim of this study was to use a combination of physiologically based pharmacokinetic (PBPK) modeling and urinary glucose excretion (UGE) modeling to predict the time profiles of pharmacokinetics (PK) and UGE for the sodium-glucose cotransporter 2 (SGLT2) inhibitor empagliflozin (EMP). Additionally, the study aims to explore the compensatory effect of SGLT1 in renal glucose reabsorption (RGR) when SGLT2 is inhibited. The PBPK-UGE model was developed using physicochemical and biochemical properties, renal physiological parameters, binding...
Source: The Journal of Clinical Pharmacology - February 16, 2024 Category: Drugs & Pharmacology Authors: Xian Ping Guopeng Wang Dongmei Gao Source Type: research
Sparsentan: the first and only non-immunosuppressive therapy for the reduction of proteinuria in IgA nephropathy
Expert Rev Clin Immunol. 2024 Feb 16. doi: 10.1080/1744666X.2024.2319132. Online ahead of print.ABSTRACTINTRODUCTION: IgA nephropathy is one of the most common forms of glomerular disease. Patients with persistent proteinuria are at increased risk of progression to kidney failure. There is a significant need for safe and effective therapies to lower proteinuria in these patients. Sparsentan is a non-immunosuppressive agent that acts as a dual angiotensin and endothelin receptor antagonist. It lowers proteinuria in experimental models of glomerular disease and in affected patients.AREAS COVERED: This review covers the immun...
Source: Expert Review of Clinical Immunology - February 16, 2024 Category: Allergy & Immunology Authors: Howard Trachtman Radko Komers Jula Inrig Source Type: research
Mechanistic Modeling of Empagliflozin: Predicting Pharmacokinetics, Urinary Glucose Excretion, and Investigating Compensatory Role of SGLT1 in Renal Glucose Reabsorption
J Clin Pharmacol. 2024 Feb 16. doi: 10.1002/jcph.2413. Online ahead of print.ABSTRACTThe aim of this study was to use a combination of physiologically based pharmacokinetic (PBPK) modeling and urinary glucose excretion (UGE) modeling to predict the time profiles of pharmacokinetics (PK) and UGE for the sodium-glucose cotransporter 2 (SGLT2) inhibitor empagliflozin (EMP). Additionally, the study aims to explore the compensatory effect of SGLT1 in renal glucose reabsorption (RGR) when SGLT2 is inhibited. The PBPK-UGE model was developed using physicochemical and biochemical properties, renal physiological parameters, binding...
Source: The Journal of Clinical Pharmacology - February 16, 2024 Category: Drugs & Pharmacology Authors: Xian Ping Guopeng Wang Dongmei Gao Source Type: research
Sparsentan: the first and only non-immunosuppressive therapy for the reduction of proteinuria in IgA nephropathy
Expert Rev Clin Immunol. 2024 Feb 16. doi: 10.1080/1744666X.2024.2319132. Online ahead of print.ABSTRACTINTRODUCTION: IgA nephropathy is one of the most common forms of glomerular disease. Patients with persistent proteinuria are at increased risk of progression to kidney failure. There is a significant need for safe and effective therapies to lower proteinuria in these patients. Sparsentan is a non-immunosuppressive agent that acts as a dual angiotensin and endothelin receptor antagonist. It lowers proteinuria in experimental models of glomerular disease and in affected patients.AREAS COVERED: This review covers the immun...
Source: Expert Review of Clinical Immunology - February 16, 2024 Category: Allergy & Immunology Authors: Howard Trachtman Radko Komers Jula Inrig Source Type: research
Mechanistic Modeling of Empagliflozin: Predicting Pharmacokinetics, Urinary Glucose Excretion, and Investigating Compensatory Role of SGLT1 in Renal Glucose Reabsorption
J Clin Pharmacol. 2024 Feb 16. doi: 10.1002/jcph.2413. Online ahead of print.ABSTRACTThe aim of this study was to use a combination of physiologically based pharmacokinetic (PBPK) modeling and urinary glucose excretion (UGE) modeling to predict the time profiles of pharmacokinetics (PK) and UGE for the sodium-glucose cotransporter 2 (SGLT2) inhibitor empagliflozin (EMP). Additionally, the study aims to explore the compensatory effect of SGLT1 in renal glucose reabsorption (RGR) when SGLT2 is inhibited. The PBPK-UGE model was developed using physicochemical and biochemical properties, renal physiological parameters, binding...
Source: The Journal of Clinical Pharmacology - February 16, 2024 Category: Drugs & Pharmacology Authors: Xian Ping Guopeng Wang Dongmei Gao Source Type: research
Sparsentan: the first and only non-immunosuppressive therapy for the reduction of proteinuria in IgA nephropathy
Expert Rev Clin Immunol. 2024 Feb 16. doi: 10.1080/1744666X.2024.2319132. Online ahead of print.ABSTRACTINTRODUCTION: IgA nephropathy is one of the most common forms of glomerular disease. Patients with persistent proteinuria are at increased risk of progression to kidney failure. There is a significant need for safe and effective therapies to lower proteinuria in these patients. Sparsentan is a non-immunosuppressive agent that acts as a dual angiotensin and endothelin receptor antagonist. It lowers proteinuria in experimental models of glomerular disease and in affected patients.AREAS COVERED: This review covers the immun...
Source: Expert Review of Clinical Immunology - February 16, 2024 Category: Allergy & Immunology Authors: Howard Trachtman Radko Komers Jula Inrig Source Type: research
Mechanistic Modeling of Empagliflozin: Predicting Pharmacokinetics, Urinary Glucose Excretion, and Investigating Compensatory Role of SGLT1 in Renal Glucose Reabsorption
J Clin Pharmacol. 2024 Feb 16. doi: 10.1002/jcph.2413. Online ahead of print.ABSTRACTThe aim of this study was to use a combination of physiologically based pharmacokinetic (PBPK) modeling and urinary glucose excretion (UGE) modeling to predict the time profiles of pharmacokinetics (PK) and UGE for the sodium-glucose cotransporter 2 (SGLT2) inhibitor empagliflozin (EMP). Additionally, the study aims to explore the compensatory effect of SGLT1 in renal glucose reabsorption (RGR) when SGLT2 is inhibited. The PBPK-UGE model was developed using physicochemical and biochemical properties, renal physiological parameters, binding...
Source: The Journal of Clinical Pharmacology - February 16, 2024 Category: Drugs & Pharmacology Authors: Xian Ping Guopeng Wang Dongmei Gao Source Type: research
Sparsentan: the first and only non-immunosuppressive therapy for the reduction of proteinuria in IgA nephropathy
Expert Rev Clin Immunol. 2024 Feb 16. doi: 10.1080/1744666X.2024.2319132. Online ahead of print.ABSTRACTINTRODUCTION: IgA nephropathy is one of the most common forms of glomerular disease. Patients with persistent proteinuria are at increased risk of progression to kidney failure. There is a significant need for safe and effective therapies to lower proteinuria in these patients. Sparsentan is a non-immunosuppressive agent that acts as a dual angiotensin and endothelin receptor antagonist. It lowers proteinuria in experimental models of glomerular disease and in affected patients.AREAS COVERED: This review covers the immun...
Source: Expert Review of Clinical Immunology - February 16, 2024 Category: Allergy & Immunology Authors: Howard Trachtman Radko Komers Jula Inrig Source Type: research
Ketones provide an extra source of fuel for the failing heart without impairing glucose oxidation
Cardiac glucose oxidation is decreased in heart failure with reduced ejection fraction (HFrEF), contributing to a decrease in myocardial ATP production. In contrast, circulating ketones and cardiac ketone oxidation are increased in HFrEF. Since ketones compete with glucose as a fuel source, we aimed to determine whether increasing ketone concentration both chronically with the SGLT2 inhibitor, dapagliflozin, or acutely in the perfusate has detrimental effects on cardiac glucose oxidation in HFrEF, and what effect this has on cardiac ATP production. (Source: Metabolism - Clinical and Experimental)
Source: Metabolism - Clinical and Experimental - February 16, 2024 Category: Biomedical Science Authors: Simran Pherwani, David Connolly, Qiuyu Sun, Qutuba G. Karwi, Michael Carr, Kim L. Ho, Cory S. Wagg, Liyan Zhang, Jody Levasseur, Heidi Silver, Jason R.B. Dyck, Gary D. Lopaschuk Source Type: research
Sodium-glucose cotranspor ter 2 (SGLT2) inhibitors in nephrolithiasis: should we "gliflozin" patients with kidney stone disease?
J Bras Nefrol. 2024 Feb 12:S0101-28002024005005603. doi: 10.1590/2175-8239-JBN-2023-0146en. Online ahead of print.ABSTRACTThe prevalence of nephrolithiasis is increasing worldwide. Despite advances in understanding the pathogenesis of lithiasis, few studies have demonstrated that specific clinical interventions reduce the recurrence of nephrolithiasis. The aim of this review is to analyze the current data and potential effects of iSGLT2 in lithogenesis and try to answer the question: Should we also "gliflozin" our patients with kidney stone disease?PMID:38358913 | DOI:10.1590/2175-8239-JBN-2023-0146en (Source: Jornal Brasileiro de Nefrologia)
Source: Jornal Brasileiro de Nefrologia - February 15, 2024 Category: Urology & Nephrology Authors: Mauricio de Carvalho Ita Pfeferman Heilberg Source Type: research
Impact of Initiating a GLP1 Agonist and/or SGLT2 Inhibitor Therapy on De-Escalation and Discontinuation of Insulin and Diabetes Control When Managed by an Interprofessional Collaborative Team
CONCLUSION: Most patients initially overbasalized on insulin experienced a reduction in overbasalization after initiating GLP1 RA and/or SGLT2i. There was a notable A1C reduction, de-escalation, and deprescribing of insulin in patients receiving interprofessional collaborative care.PMID:38353180 | DOI:10.1177/21501319241231398 (Source: Primary Care)
Source: Primary Care - February 14, 2024 Category: Primary Care Authors: Megan Champion Gabriel Wills Avila Angelica E Garcia Faviola M Álvarez Delgado Connie A Valdez Source Type: research
